JPMorgan analyst Brian Ossenbeck downgraded ArcBest to Neutral from Overweight with a price target of $127, down from $145. The analyst says ArcBest “screens poorly” on risk/reward again this quarter and JPMOrgan is still materially below 2025 consensus estimates. The firm is concerned the share donor narrative “will be difficult to shake” as the industry laps the impact of Yellow’s bankruptcy and ABF also faces declining core weight per shipment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCB: